Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 9, 2006, Pages 1928-1930

  Lijfering, Willem M ^a   Ten Kate, M K ^a   Sprenger, H G ^a   van der Meer, J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BLOOD CLOTTING FACTOR 8C; PROTEIN S; PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; SEX DIFFERENCE; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; ARTERIAL OCCLUSIVE DISEASES; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK; THROMBOSIS;

EID: 33747172502     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02047.x     Document Type: Article

References (10)

1. Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The adult/adolescent spectrum of HIV disease project. AIDS 2000; 14: 32-4.
2. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-86.
3. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
4. Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104: 143-8.
5. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
6. Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyak K, van Der Meer J, Prins MH, Buller HR. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135: 322-7.
7. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, Melton LJ III. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-63.
8. Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81: 1801-7.
9. Bissuel F, Berruyer M, Causse X, Dechavanne M, Trepo C. Acquired protein S deficiency: Correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr 1992; 5: 484-9.
10. Thom TJ, Kannel WB, Silbershatz H, D'Agostino RB. Incidence, prevalence, and mortality of cardiovascular diseases in the United States. In: Alexander RW, Schlant RC, Fuster V, eds. Hurst's the Heart, 9th edn. New York, NY, USA: McGraw-Hill, 1998: 3-17.